Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Issued (2020 - 2025)

Foghorn Therapeutics has reported Shares Issued over the past 6 years, most recently at $483000.0 for Q4 2025.

  • Quarterly results put Shares Issued at $483000.0 for Q4 2025, up 100.48% from a year ago — trailing twelve months through Dec 2025 was $483000.0 (down 81.51% YoY), and the annual figure for FY2025 was $483000.0, down 81.51%.
  • Shares Issued for Q4 2025 was $483000.0 at Foghorn Therapeutics, up from -$393000.0 in the prior quarter.
  • Over the last five years, Shares Issued for FHTX hit a ceiling of $102.2 million in Q2 2024 and a floor of -$100.8 million in Q4 2024.
  • Median Shares Issued over the past 5 years was $293500.0 (2022), compared with a mean of $2.7 million.
  • Peak annual rise in Shares Issued hit 100329.41% in 2024, while the deepest fall reached 5768.67% in 2024.
  • Foghorn Therapeutics' Shares Issued stood at $41.5 million in 2021, then tumbled by 99.96% to $16000.0 in 2022, then surged by 11012.5% to $1.8 million in 2023, then crashed by 5768.67% to -$100.8 million in 2024, then skyrocketed by 100.48% to $483000.0 in 2025.
  • The last three reported values for Shares Issued were $483000.0 (Q4 2025), -$393000.0 (Q3 2025), and $254000.0 (Q2 2025) per Business Quant data.